A phase I/IIa clinical trial of BT1718 in patients with advanced solid tumors
Phase of Trial: Phase I/II
Latest Information Update: 13 Feb 2018
At a glance
- Drugs BT 1718 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 13 Feb 2018 According to a Cancer Research UK media release, first patient has been dosed in this trial.
- 13 Feb 2018 Status changed from planning to recruiting, according to a Cancer Research UK media release.
- 06 Jul 2017 According to Pepscan Therapeutics media release, Cancer Research UK, will sponsor and fund the trial.